Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Biosurfit

Explore full profile

Develops breakthrough technologies that enable fast, precise and affordable blood analysis

Azambuja, PortugalFounded 2006Biotech & Life Sciences
Valuation $50–100M Last recorded · 2018
Revenue $1–10M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Biosurfit and the history behind them.

About Biosurfit

Biosurfit is a pioneering company in the field of Point-of-Care Testing (POCT), which means they provide medical testing that can be done at or near the site of patient care. This startup specializes in creating innovative diagnostic solutions that deliver lab-quality results quickly and accurately. Their primary product is a multi-parameter POCT system that integrates various types of tests, such as immunoassays, hematology, and clinical chemistry, into a single platform. This allows healthcare providers to perform multiple tests using one device, saving time and improving efficiency.

Biosurfit serves a diverse range of clients, including hospitals, clinics, and companies that need to conduct rapid and reliable health assessments. For instance, they have successfully helped companies like Staples ensure the safety of their employees by providing quick and accurate COVID-19 testing.

Operating in the healthcare diagnostics market, Biosurfit stands out due to its innovative approach and the quality of its products. Their business model revolves around selling both the diagnostic instruments and the disposable discs used for various tests, such as CRP (C-reactive protein), HbA1c (glycosylated hemoglobin), and total white blood cells. These disposable discs are essential for the operation of their testing devices, ensuring a recurring revenue stream.

Biosurfit makes money by selling their diagnostic instruments and the consumable discs required for each test. This model not only provides an initial revenue boost from the sale of the instruments but also ensures ongoing income from the repeat purchase of the disposable discs. Their products are recognized for their stability, ease of use, and the ability to deliver fast results, which helps healthcare providers make better decisions quickly.

In summary, Biosurfit is a forward-thinking company that is transforming the POCT market with its multi-parameter diagnostic solutions, catering to healthcare providers and companies needing rapid, reliable testing.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2006
Headquarters
Azambuja, Portugal
Employees
57
Open positions
8
Dealroom signal
67.1/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotech & Life Sciences, Diabetes, Analytics, Biotechnology, Health Diagnostics, Spinout, Sustainable Development Goals, Hard Tech, Horizon Europe, Health It
Business model
Manufacturing
Client focus
b2b

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Dec 2018 $11M $44M PME Investimentos · Boule Diagnostics —
GRANT✓Other financing Oct 2016 $55K — European Innovation Council —
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Biosurfit website traffic

Latest recorded traffic for Biosurfit is 180 monthly website visits, down 90% over the last three months. Biosurfit's team grew 1.8% over the past year.

Latest monthly visits180 3-month web change-90% 1-year team growth+1.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
OiviPreventing blindness among diabetes patients by deploying an AI-camera for automated diagnosis of retinal diseases Oslo, Norway Operational 53 $10M $12M
THERAPANACEADevotion to Innovation, Compassion for Patients, Artificial Intelligence for Cancer Care Paris, France Operational
GlyCardial DiagnosticsSpin-off company of the Catalan Institute of Cardiovascular Sciences (ICCC) and the Spanish National Research Council (CSIC) focused on the development of a novel in vitro diagnostic device for myocardial ischemia Barcelona, Spain Operational
FeopsCutting-edge technology that creates digital twins from cardiac scans Ghent, Belgium Acquired
MRIguidanceThe first medical imaging technique that creates 3D images of both bone and soft tissue, enables orthopaedic and neurosurgeons to plan and guide minimally invasive surgical procedures Utrecht, Netherlands Operational
PepticomAn Artificial Intelligence (AI) company for the discovery of novel molecules in the Pharmaceutical and Agricultural markets Jerusalem, Israel Operational
AntegenesGenetic tests for personalized cancer risk prevention Tartu, Estonia Operational
EarlySightDeveloping a medical device to help doctors detect and treat eye diseases at an early-stage thanks to precise measurement of the eye condition Geneva, Switzerland Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Caixa Capital
  • Beta Capital
  • European Innovation Council

Series A2 investors entered at this stage

  • Boule Diagnostics
  • PME Investimentos

Series B and later1 investor entered at this stage

  • European Investment Bank

Other known investors3 additional known investors

  • Tec Labs
  • University of Lisbon
  • 200M
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇵🇹 Portugal80%
🇺🇸 United States2.9%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Biosurfit on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Biosurfit’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.